Literature DB >> 24510650

Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II.

Britt A Johnson1, Otto P van Diggelen, Angela Dajnoki, Olaf A Bodamer.   

Abstract

Mucopolysaccharidosis type II (MPS II) is an X-linked lysosomal storage disorder caused by a deficiency of iduronate 2-sulfatase (IDS). Progressive, intralysosomal accumulation of the glycosaminoglycans (GAGs) dermatan and heparan sulfate in almost all tissues leads to multi-organ involvement in affected males but to virtual absence of symptoms in heterozygote female carriers due to preferential inactivation of the mutant allele. Diagnosis of MPS II in males is based on IDS analysis in leukocytes, fibroblasts, plasma, or dried blood spots (DBS), whereas IDS activities may be within the normal range in heterozygote females. The advent of fluorometric and mass spectrometry methods for enzyme analysis in DBS has simplified the diagnostic approach for MPS II males. Molecular analysis of the IDS gene confirms the diagnosis of MPS II in males and is the only diagnostic test to confirm carrier status in females. This unit provides detailed analytical protocols for measurement of IDS activity in DBS and plasma using a fluorometric assay.
Copyright © 2013 John Wiley & Sons, Inc.

Entities:  

Keywords:  Hunter Syndrome; MPS II; alpha-iduronate-2-sulfatase; dried blood spot; fluorometry; glycosaminoglycans; mucopolysaccharide; mucopolysaccharidosis Type II

Mesh:

Substances:

Year:  2013        PMID: 24510650     DOI: 10.1002/0471142905.hg1714s79

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  3 in total

1.  A Rapid Two-Step Iduronate-2-Sulfatatse Enzymatic Activity Assay for MPSII Pharmacokinetic Assessment.

Authors:  Mitra Azadeh; Luying Pan; Yongchang Qiu; Ruben Boado
Journal:  JIMD Rep       Date:  2017-06-23

2.  Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.

Authors:  Shaukat A Khan; Robert W Mason; Roberto Giugliani; Kenji Orii; Toshiyuki Fukao; Yasuyuki Suzuki; Seiji Yamaguchi; Hironori Kobayashi; Tadao Orii; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-17       Impact factor: 4.797

3.  Mucopolysaccharidosis type II detection by Naïve Bayes Classifier: An example of patient classification for a rare disease using electronic medical records from the Canadian Primary Care Sentinel Surveillance Network.

Authors:  Behrouz Ehsani-Moghaddam; John A Queenan; Jennifer MacKenzie; Richard V Birtwhistle
Journal:  PLoS One       Date:  2018-12-19       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.